Julia Starlinger1,2, Verena J M M Schrier1,3, Carin Y Smith4, Joanne Song5, Elizabeth A Stewart6,7,8, Liliana Gazzuola Rocca9, Peter C Amadio1, Walter A Rocca8,9,10. 1. Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN. 2. Department of Orthopedics and Trauma-Surgery, Medical University of Vienna, Vienna, Austria. 3. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 5. Mayo Clinic Alix School of Medicine, Rochester, MN. 6. Department of Surgery, Mayo Clinic, Rochester, MN. 7. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN. 8. Women's Health Research Center, Mayo Clinic, Rochester, MN. 9. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 10. Department of Neurology, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: The incidence of carpal tunnel syndrome (CTS) is higher in women, and peaks around the age of menopause. Therefore, we investigated whether bilateral oophorectomy is associated with an increased risk of severe CTS. METHODS: We included all of the 1,653 premenopausal women who underwent bilateral oophorectomy for a nonmalignant indication between 1988 and 2007, and a random sample of 1,653 age-matched referent women who did not undergo bilateral oophorectomy in Olmsted County, MN. Diagnoses of CTS assigned to women over their entire lifetime were identified in these two cohorts. The risk of de novo severe CTS after bilateral oophorectomy (or index date) was evaluated using Cox proportional hazards models adjusted for potential confounders. RESULTS: Bilateral oophorectomy was associated with an increased risk of severe CTS (adjusted hazard ratio 1.65, 95% confidence interval 1.20-2.25). The risk was suggestively greater in women with lower body mass index, nulliparity, and with a benign ovarian indication for oophorectomy (nonsignificant interactions). We did not observe a protective effect of estrogen therapy after the oophorectomy. The findings were similar in secondary analyses considering the incidence of CTS of any severity or idiopathic CTS. CONCLUSIONS: The risk of severe CTS, common in perimenopausal women, is increased after bilateral oophorectomy. The association may be causal or due to confounding. Therefore, the precise biological mechanisms explaining the association and the absence of a mitigating effect of estrogen therapy should be further investigated.
OBJECTIVE: The incidence of carpal tunnel syndrome (CTS) is higher in women, and peaks around the age of menopause. Therefore, we investigated whether bilateral oophorectomy is associated with an increased risk of severe CTS. METHODS: We included all of the 1,653 premenopausal women who underwent bilateral oophorectomy for a nonmalignant indication between 1988 and 2007, and a random sample of 1,653 age-matched referent women who did not undergo bilateral oophorectomy in Olmsted County, MN. Diagnoses of CTS assigned to women over their entire lifetime were identified in these two cohorts. The risk of de novo severe CTS after bilateral oophorectomy (or index date) was evaluated using Cox proportional hazards models adjusted for potential confounders. RESULTS: Bilateral oophorectomy was associated with an increased risk of severe CTS (adjusted hazard ratio 1.65, 95% confidence interval 1.20-2.25). The risk was suggestively greater in women with lower body mass index, nulliparity, and with a benign ovarian indication for oophorectomy (nonsignificant interactions). We did not observe a protective effect of estrogen therapy after the oophorectomy. The findings were similar in secondary analyses considering the incidence of CTS of any severity or idiopathic CTS. CONCLUSIONS: The risk of severe CTS, common in perimenopausal women, is increased after bilateral oophorectomy. The association may be causal or due to confounding. Therefore, the precise biological mechanisms explaining the association and the absence of a mitigating effect of estrogen therapy should be further investigated.
Authors: Y Roquelaure; S Mechali; C Dano; S Fanello; F Benetti; D Bureau; J Mariel; Y H Martin; F Derriennic; D Penneau-Fontbonne Journal: Scand J Work Environ Health Date: 1997-10 Impact factor: 5.024
Authors: Walter A Rocca; Brandon R Grossardt; Scott M Brue; Cynthia M Bock-Goodner; Alanna M Chamberlain; Patrick M Wilson; Lila J Finney Rutten; Jennifer L St Sauver Journal: Int J Epidemiol Date: 2018-04-01 Impact factor: 7.196
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: Carlos A Cañas; Carlos J Osorio; Nicolás Coronel; Magda C Cepeda; Jorge H Izquierdo; Fabio Bonilla-Abadía Journal: Rheumatol Int Date: 2013-01-19 Impact factor: 2.631
Authors: Walter A Rocca; Barbara P Yawn; Jennifer L St Sauver; Brandon R Grossardt; L Joseph Melton Journal: Mayo Clin Proc Date: 2012-11-28 Impact factor: 7.616
Authors: Walter A Rocca; Liliana Gazzuola Rocca; Carin Y Smith; Brandon R Grossardt; Stephanie S Faubion; Lynne T Shuster; James L Kirkland; Elizabeth A Stewart; Virginia M Miller Journal: J Gerontol A Biol Sci Med Sci Date: 2017-09-01 Impact factor: 6.053
Authors: Tala Al-Rousan; Jeffrey A Sparks; Mary Pettinger; Rowan Chlebowski; JoAnn E Manson; Andrew M Kauntiz; Robert Wallace Journal: PLoS One Date: 2018-12-04 Impact factor: 3.240
Authors: Walter A Rocca; Liliana Gazzuola-Rocca; Carin Y Smith; Brandon R Grossardt; Stephanie S Faubion; Lynne T Shuster; James L Kirkland; Elizabeth A Stewart; Virginia M Miller Journal: Mayo Clin Proc Date: 2016-09-29 Impact factor: 7.616